GlassScriptPhysician profile
Aaron Stewart
NPI 1205055852
$10,823.20
in general payments reported to CMS, 2019-2025
30 companies · $3,172 in 2025
The $3,172 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,829 · 2023: $2,916 · 2024: $2,906 · 2025: $3,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,813 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,813.45 |
| Education | $180.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,440.88 | 2022-2025 | |
| Amgen INC. | $1,674.07 | 2022-2025 | Enbrel, Tavneos, Otezla |
| Janssen Biotech, INC. | $1,208.51 | 2024-2025 | Tremfya, Simponi Aria |
| Mallinckrodt Hospital Products INC. | $1,014.02 | 2022-2025 | Acthar |
| Lilly USA, LLC | $810.66 | 2022-2025 | Taltz, Zepbound |
| Ucb, INC. | $576.50 | 2025 | Bimzelx |
| Glaxosmithkline, LLC. | $527.75 | 2022-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $457.70 | 2022-2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $306.76 | 2023-2025 | |
| Fresenius Kabi USA, LLC | $222.93 | 2023-2024 | Idacio |
| Organon LLC | $203.84 | 2022-2024 | Renflexis, Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.68 | 2022-2025 | Ofev, Cyltezo |
| Astrazeneca Pharmaceuticals LP | $174.73 | 2022-2024 | Saphnelo |
| Genentech USA, INC. | $151.95 | 2022-2025 | Actemra |
| Pfizer INC. | $146.83 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $114.49 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $111.54 | 2022-2023 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $83.62 | 2022-2024 | Ultomiris, Strensiq |
| Sandoz INC. | $77.93 | 2024-2025 | Jubbonti, Hyrimoz |
| Actelion Pharmaceuticals US, INC. | $57.85 | 2024-2025 | Uptravi, Opsumit |
| Fidia Pharma USA INC. | $57.06 | 2023-2025 | Hymovis, Triluron |
| Sobi, INC | $40.76 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $25.48 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $23.96 | 2024 | Arcalyst |
| Aurinia Pharma U.S., INC. | $22.78 | 2025 | Lupkynis |
| Takeda Pharmaceuticals U.S.A., INC. | $22.65 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $21.17 | 2023 | Arcalyst |
| Teva Pharmaceuticals USA, INC. | $19.87 | 2024 | Truxima |
| Scilex Pharmaceuticals INC. | $17.36 | 2025 | |
| Ibsa Pharma INC. | $16.87 | 2024 | Tirosint, Licart, Flector |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.